MAYN.F Stock Overview
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Mayne Pharma Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$4.47 |
| 52 Week High | AU$4.59 |
| 52 Week Low | AU$1.90 |
| Beta | 1.32 |
| 1 Month Change | -0.67% |
| 3 Month Change | 30.51% |
| 1 Year Change | 69.96% |
| 3 Year Change | -38.09% |
| 5 Year Change | -51.68% |
| Change since IPO | -51.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| MAYN.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -2.2% | -3.7% |
| 1Y | 70.0% | 11.6% | 20.5% |
Return vs Industry: MAYN.F exceeded the US Pharmaceuticals industry which returned 11.7% over the past year.
Return vs Market: MAYN.F exceeded the US Market which returned 20.2% over the past year.
Price Volatility
| MAYN.F volatility | |
|---|---|
| MAYN.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MAYN.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine MAYN.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | Shawn O’Brien | www.maynepharma.com |
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. The company operates through four segments: International Branded Products, and Portfolio Product Division. It provides oral drug delivery systems; and contract development and manufacturing services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women’s health, and infectious disease therapeutic areas.
Mayne Pharma Group Limited Fundamentals Summary
| MAYN.F fundamental statistics | |
|---|---|
| Market cap | US$346.80m |
| Earnings (TTM) | -US$175.94m |
| Revenue (TTM) | US$204.88m |
1.7x
P/S Ratio-2.0x
P/E RatioIs MAYN.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MAYN.F income statement (TTM) | |
|---|---|
| Revenue | AU$319.28m |
| Cost of Revenue | AU$145.07m |
| Gross Profit | AU$174.21m |
| Other Expenses | AU$448.39m |
| Earnings | -AU$274.18m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 23, 2024
| Earnings per share (EPS) | -3.38 |
| Gross Margin | 54.56% |
| Net Profit Margin | -85.87% |
| Debt/Equity Ratio | 5.5% |
How did MAYN.F perform over the long term?
See historical performance and comparison